The high tumor mutational burden, typical phenotype of MSI-high tumors, could activate multiple oncogenic signals and thus negatively interfere with the therapeutic inhibition of a single pathway, i.e., EGFR blockade. This evidence concerns the gene EGFR and neoplasm.